AEON Biopharma, Inc. | 8-K: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.14 13:32
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.39.

EBIT: As of FY2025 Q3, the actual value is USD -2.493 M.

Financial Metrics by Segment

Segment Revenue

  • Not explicitly detailed in the provided reference.

Operational Metrics

  • Net Loss: For the three months ended September 30, 2025, net loss was $4,538 thousand, compared to a net loss of $6,171 thousand for the same period in 2024. For the nine months ended September 30, 2025, net loss was $2,085 thousand, compared to a net income of $39,923 thousand for the same period in 2024.
  • Operating Costs and Expenses: Total operating costs and expenses for the three months ended September 30, 2025, were $2,493 thousand, compared to $4,016 thousand for the same period in 2024. For the nine months ended September 30, 2025, total operating costs and expenses were $7,292 thousand, compared to - $75,306 thousand for the same period in 2024.
  • Operating Loss: For the three months ended September 30, 2025, operating loss was $2,493 thousand, compared to an operating loss of $4,016 thousand for the same period in 2024. For the nine months ended September 30, 2025, operating loss was $7,292 thousand, compared to an operating income of $75,306 thousand for the same period in 2024.

Cash Flow

  • Cash and Cash Equivalents: As of September 30, 2025, cash and cash equivalents were $5,927 thousand, compared to $13 thousand as of December 31, 2024.

Unique Metrics

  • Convertible Notes: Convertible notes at fair value, including related party amounts, were $17,051 thousand as of September 30, 2025, compared to $11,689 thousand as of December 31, 2024.
  • Warrant Liability: Warrant liability was $2,338 thousand as of September 30, 2025, compared to $1,187 thousand as of December 31, 2024.

Outlook / Guidance

  • AEON Biopharma expects the recent $6 million PIPE financing and proposed Daewoong note exchange to strengthen its balance sheet, reduce outstanding debt by more than 90%, and extend its cash runway into the second quarter of 2026.
  • The company has an FDA Type 2a meeting scheduled for November 19, 2025, to review its analytical development plan and initial data.
  • AEON Biopharma aims to accelerate the ABP-450 biosimilar program by up to six months.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.